Dose-Response Relationship

Dose-Response Relationship

The dose-response relationship is a foundational concept in pharmacology that describes how the magnitude of a drug’s effect changes as a function of its dose. In clinical development, characterizing this relationship is essential for selecting optimal doses for large-scale Phase 3 trials. A clear dose-response signal—where higher doses produce greater therapeutic effects—provides strong evidence that the observed benefit is genuinely drug-related rather than a chance finding, and helps regulators assess the benefit-risk profile across different dose levels.

Phase 2 dose-ranging trials are specifically designed to map the dose-response curve by testing multiple dose levels against placebo. Key considerations include identifying the minimum effective dose, the dose at which efficacy plateaus (the ceiling effect), and the dose beyond which side effects increase disproportionately relative to additional benefit. An ideal dose-response profile shows a steep initial rise in efficacy with increasing dose, followed by a plateau where further dose increases provide diminishing returns while adverse events continue to rise.

Retatrutide demonstrated a remarkably clear dose-response relationship in its Phase 2 program. In the obesity trial, weight loss increased progressively from -8.7% at the 1 mg dose to -24.2% at the 12 mg dose over 48 weeks, with the highest dose group showing the weight loss curve still trending downward at study completion. Similarly, HbA1c reductions in the type 2 diabetes trial ranged from -1.39% at 1 mg to -2.02% at 12 mg. This consistent dose-response pattern across both indications supported the selection of higher dose levels for the Phase 3 TRIUMPH program and reinforced the causal relationship between retatrutide exposure and clinical outcomes.